Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer

Radiotherapy and Oncology

Volumn 111, Issue 3, 2014, Pages 393-399

  Weber, Damien C ^a,b   Hurkmans, Coen W ^b,c   Melidis, Christos ^b   Budach, Wilfried ^d   Langendijk, Johannes H ^e   Peters, Lester J ^f   Grégoire, Vincent ^g   Maingon, Philippe ^h   Combescure, Christophe ⁱ  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b EORTC DATA CENTER   (Belgium)

^c CATHARINA HOSPITAL   (Netherlands)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cost effectiveness; Head and neck cancer; Quality assurances; Quality adjusted life years; Radiotherapy

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY ASSURANCE IN RADIOTHERAPY; QUALITY CONTROL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; STATISTICAL MODEL; TREATMENT FAILURE; CONTROLLED STUDY; DATA BASE; PATIENT CODING;

COST-EFFECTIVENESS; HEAD AND NECK CANCER; QUALITY ASSURANCES; QUALITY-ADJUSTED-LIFE-YEARS; RADIOTHERAPY;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COST-BENEFIT ANALYSIS; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, STATISTICAL; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 84905271698     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.04.015     Document Type: Article

References (23)

1. T. Budiharto, K. Haustermans, and E. Van Cutsem et al. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma Radiat Oncol 3 2008 30
2. T. Budiharto, E. Musat, and P. Poortmans et al. Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century Radiother Oncol 88 2008 403 410
3. C. Castelli, C. Combescure, Y. Foucher, and J.P. Daures Cost-effectiveness analysis in colorectal cancer using a semi-Markov model Stat Med 26 2007 5557 5571 (Pubitemid 351193581)
4. Y.J. Chen, J.V. Kuo, N.S. Ramsinghani, and M.S. Al-Ghazi Intensity-modulated radiotherapy for previously irradiated, recurrent head-and-neck cancer Med Dosim 27 2002 171 176 (Pubitemid 34553480)
5. M. Coskun, W. Straube, and C.W. Hurkmans et al. Quality assurance of radiotherapy in the ongoing EORTC 22042-26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case reviews Radiat Oncol 8 2013 23
6. H.A. Drummond, S.C. Grifoni, and N.L. Jernigan A new trick for an old dogma: ENaC proteins as mechanotransducers in vascular smooth muscle Physiology 23 2008 23 31
7. M. Drummond, M. Sculpher, G. Torrance, B. O'Brien, and G. Stoddart Methods for the economic evaluation of health care programs 2005 Oxford University Press Oxford
8. A. Fairchild, L. Collette, and C.W. Hurkmans et al. Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? Eur J Cancer 48 2012 3232 3239
9. M.C. Koshy, J.C. Landry, and S.X. Cavanaugh et al. A challenge to the therapeutic nihilism of ESPAC-1 Int J Radiat Oncol Biol Phys 61 2005 965 966 (Pubitemid 40340890)
10. R.E. Langley, R.J. Stephens, and M. Nankivell et al. Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? Clin Oncol (R Coll Radiol) 25 2013 e23 e30
11. R. Luengo-Fernandez, J. Leal, A. Gray, and R. Sullivan Economic burden of cancer across the European Union: a population-based cost analysis Lancet Oncol 14 2013 1165 1174
12. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744
13. J.P. Neoptolemos, D.D. Stocken, and H. Friess et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210 (Pubitemid 38339364)
14. N. Ohri, X. Shen, A.P. Dicker, L.A. Doyle, A.S. Harrison, and T.N. Showalter Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials J Natl Cancer Inst 105 2013 387 393
15. L.J. Peters, B. O'Sullivan, and J. Giralt et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 J Clin Oncol 28 2010 2996 3001
16. V.P. Retel, L. van der Molen, and F.J. Hilgers et al. A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy BMC Cancer 11 2011 475
17. D. Rischin, L.J. Peters, and B. O'Sullivan et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group J Clin Oncol 28 2010 2989 2995
18. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338 (Pubitemid 24013155)
19. R. Sullivan, J. Peppercorn, and K. Sikora et al. Delivering affordable cancer care in high-income countries Lancet Oncol 12 2011 933 980
20. J.G. Trogdon, F.K. Tangka, D.U. Ekwueme, G.P. Guy Jr., I. Nwaise, and D. Orenstein State-level projections of cancer-related medical care costs: 2010 to 2020 Am J Manag Care 18 2012 525 532
21. E. Van de Werf, J. Verstraete, and Y. Lievens The cost of radiotherapy in a decade of technology evolution Radiother Oncol 102 1 2012 148 153
22. D.C. Weber, P.M. Poortmans, C.W. Hurkmans, E. Aird, A. Gulyban, and A. Fairchild Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting Radiother Oncol 100 2011 150 156
23. D.C. Weber, M. Tomsej, C. Melidis, and C.W. Hurkmans QA makes a clinical trial stronger: evidence-based medicine in radiation therapy Radiother Oncol 105 1 2012 4 8